Jump to main content
Jump to site search

Issue 3, 2017
Previous Article Next Article

DNA–affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

Author affiliations

Abstract

In this study, we have prepared a DNA–affibody nanoparticle which mimics a antibody in its ability to specifically target the HER2 receptor. This nanoparticle has a smaller size (95 kDa) than the monoclonal antibody, trastuzumab (150 kDa) and at least two-fold greater activity toward BT474 cells than trastuzumab. The DNA in this nanoparticle structure has two functions, namely as a support to anchor two affibody molecules and as a vehicle to non-covalently bind multiple copies of a small molecule drug for drug delivery. Each DNA–affibody nanoparticle can bind ∼53 molecules of doxorubicin (DOX) to form a complex, which exhibits greater selectivity toward and inhibition of breast cancer cells overexpressing HER2 than doxorubicin does. As expected, the nanoparticle exhibits lesser inhibition of cells expressing HER2 at a low level. Thus, the nanoparticle represents a highly efficacious agent for inhibiting cancer cells which overexpress HER2, but with low toxicity toward normal cells.

Graphical abstract: DNA–affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

Back to tab navigation

Supplementary files

Article information


Submitted
21 Oct 2016
Accepted
08 Dec 2016
First published
09 Dec 2016

Chem. Commun., 2017,53, 573-576
Article type
Communication

DNA–affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2

Y. Zhang, S. Jiang, D. Zhang, X. Bai, S. M. Hecht and S. Chen, Chem. Commun., 2017, 53, 573
DOI: 10.1039/C6CC08495H

Social activity

Search articles by author

Spotlight

Advertisements